Trinity Biotech PLC
NASDAQ:TRIB

Watchlist Manager
Trinity Biotech PLC Logo
Trinity Biotech PLC
NASDAQ:TRIB
Watchlist
Price: 1.22 USD -6.15% Market Closed
Market Cap: 11.5m USD
Have any thoughts about
Trinity Biotech PLC?
Write Note

Trinity Biotech PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Trinity Biotech PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Trinity Biotech PLC
NASDAQ:TRIB
Income from Continuing Operations
-$22.3m
CAGR 3-Years
-146%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Medtronic PLC
NYSE:MDT
Income from Continuing Operations
$4B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
3%
STERIS plc
NYSE:STE
Income from Continuing Operations
$604.5m
CAGR 3-Years
34%
CAGR 5-Years
12%
CAGR 10-Years
17%
No Stocks Found

Trinity Biotech PLC
Glance View

Market Cap
11.5m USD
Industry
Health Care

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.

TRIB Intrinsic Value
7.13 USD
Undervaluation 83%
Intrinsic Value
Price

See Also

What is Trinity Biotech PLC's Income from Continuing Operations?
Income from Continuing Operations
-22.3m USD

Based on the financial report for Jun 30, 2024, Trinity Biotech PLC's Income from Continuing Operations amounts to -22.3m USD.

What is Trinity Biotech PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
5%

Over the last year, the Income from Continuing Operations growth was 51%. The average annual Income from Continuing Operations growth rates for Trinity Biotech PLC have been -146% over the past three years , 5% over the past five years .

Back to Top